Nothing's Inhibiting This Drug -- Yet

Today, Brenton Flynn looks at Abbott Labs' favorable news for a key drug but cautions that the news should be taken with a grain of salt. When Abbott Labs spins itself off to become two companies, this drug will make up a hefty portion of the revenue for AbbVie, just in time for it to fall off the patent cliff.

When it comes to do-or-die businesses, the biotech industry takes the cake. Arena Pharmaceuticals is one recent success story in the industry after gaining FDA approval for its innovative obesity drug. While the future looks bright for Arena, there are still plenty of obstacles ahead. In our brand-new premium research report on Arena Pharmaceuticals, we walk investors through the must-know opportunities and threats facing the company. Since key news can develop quickly, we're also including a full year of updates for those who sign up. Click here now to learn more.

Read Full Story

Can't get enough business news?

Sign up for Finance Report by AOL and get everything from retailer news to the latest IPOs delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.